Rondo Hatton, a famous sufferer of acromegaly whose face was distorted by the disorder.
Find information on thousands of medical conditions and prescription drugs.

Acromegaly

Acromegaly (from Greek akros "high" and megalos "large" - extremities enlargement) is a hormonal disorder that results when the pituitary gland produces excess growth hormone (hGH). Most commonly it is a benign hGH producing tumor derived from a distinct type of cells (somatotrophs) and called pituitary adenoma. more...

Home
Diseases
A
Aagenaes syndrome
Aarskog Ose Pande syndrome
Aarskog syndrome
Aase Smith syndrome
Aase syndrome
ABCD syndrome
Abdallat Davis Farrage...
Abdominal aortic aneurysm
Abdominal cystic...
Abdominal defects
Ablutophobia
Absence of Gluteal muscle
Acalvaria
Acanthocheilonemiasis
Acanthocytosis
Acarophobia
Acatalasemia
Accessory pancreas
Achalasia
Achard syndrome
Achard-Thiers syndrome
Acheiropodia
Achondrogenesis
Achondrogenesis type 1A
Achondrogenesis type 1B
Achondroplasia
Achondroplastic dwarfism
Achromatopsia
Acid maltase deficiency
Ackerman syndrome
Acne
Acne rosacea
Acoustic neuroma
Acquired ichthyosis
Acquired syphilis
Acrofacial dysostosis,...
Acromegaly
Acrophobia
Acrospiroma
Actinomycosis
Activated protein C...
Acute febrile...
Acute intermittent porphyria
Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Acute mountain sickness
Acute myelocytic leukemia
Acute myelogenous leukemia
Acute necrotizing...
Acute promyelocytic leukemia
Acute renal failure
Acute respiratory...
Acute tubular necrosis
Adams Nance syndrome
Adams-Oliver syndrome
Addison's disease
Adducted thumb syndrome...
Adenoid cystic carcinoma
Adenoma
Adenomyosis
Adenosine deaminase...
Adenosine monophosphate...
Adie syndrome
Adrenal incidentaloma
Adrenal insufficiency
Adrenocortical carcinoma
Adrenogenital syndrome
Adrenoleukodystrophy
Aerophobia
Agoraphobia
Agrizoophobia
Agyrophobia
Aicardi syndrome
Aichmophobia
AIDS
AIDS Dementia Complex
Ainhum
Albinism
Albright's hereditary...
Albuminurophobia
Alcaptonuria
Alcohol fetopathy
Alcoholic hepatitis
Alcoholic liver cirrhosis
Alektorophobia
Alexander disease
Alien hand syndrome
Alkaptonuria
Alliumphobia
Alopecia
Alopecia areata
Alopecia totalis
Alopecia universalis
Alpers disease
Alpha 1-antitrypsin...
Alpha-mannosidosis
Alport syndrome
Alternating hemiplegia
Alzheimer's disease
Amaurosis
Amblyopia
Ambras syndrome
Amelogenesis imperfecta
Amenorrhea
American trypanosomiasis
Amoebiasis
Amyloidosis
Amyotrophic lateral...
Anaphylaxis
Androgen insensitivity...
Anemia
Anemia, Diamond-Blackfan
Anemia, Pernicious
Anemia, Sideroblastic
Anemophobia
Anencephaly
Aneurysm
Aneurysm
Aneurysm of sinus of...
Angelman syndrome
Anguillulosis
Aniridia
Anisakiasis
Ankylosing spondylitis
Ankylostomiasis
Annular pancreas
Anorchidism
Anorexia nervosa
Anosmia
Anotia
Anthophobia
Anthrax disease
Antiphospholipid syndrome
Antisocial personality...
Antithrombin deficiency,...
Anton's syndrome
Aortic aneurysm
Aortic coarctation
Aortic dissection
Aortic valve stenosis
Apert syndrome
Aphthous stomatitis
Apiphobia
Aplastic anemia
Appendicitis
Apraxia
Arachnoiditis
Argininosuccinate...
Argininosuccinic aciduria
Argyria
Arnold-Chiari malformation
Arrhythmogenic right...
Arteriovenous malformation
Arteritis
Arthritis
Arthritis, Juvenile
Arthrogryposis
Arthrogryposis multiplex...
Asbestosis
Ascariasis
Aseptic meningitis
Asherman's syndrome
Aspartylglycosaminuria
Aspergillosis
Asphyxia neonatorum
Asthenia
Asthenia
Asthenophobia
Asthma
Astrocytoma
Ataxia telangiectasia
Atelectasis
Atelosteogenesis, type II
Atherosclerosis
Athetosis
Atopic Dermatitis
Atrial septal defect
Atrioventricular septal...
Atrophy
Attention Deficit...
Autoimmune hepatitis
Autoimmune...
Automysophobia
Autonomic dysfunction
Familial Alzheimer disease
Senescence
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Acromegaly most commonly affects middle-aged adults and can result in serious illness and premature death. Because of its insidious onset and slow progression, the disease is hard to diagnose in the early stages and is frequently missed for many years.

Symptoms

Features that result from high level of hGH or expanding tumor include:

  • Soft tissue swelling of the hands and feet (early sign)
  • Brow and lower jaw protrusion (enlarging jaw and hat size)
  • Enlarging hands (ring size)
  • Enlarging feet (shoe size)
  • Arthritis and carpal tunnel syndrome
  • Teeth spacing increase
  • Heart failure (major medical problem)
  • Compression of the optic chiasm leading to loss of vision in the outer visual fields
  • Diabetes mellitus
  • Hypertension

Causes

Pituitary adenoma

In over 90 percent of acromegaly patients, the overproduction of GH is caused by a benign tumor of the pituitary gland, called an adenoma. These tumors produce excess GH and, as they expand, compress surrounding brain tissues, such as the optic nerves. This expansion causes the headaches and visual disturbances that are often symptoms of acromegaly. In addition, compression of the surrounding normal pituitary tissue can alter production of other hormones, leading to changes in menstruation and breast discharge in women and impotence in men.

There is a marked variation in rates of GH production and the aggressiveness of the tumor. Some adenomas grow slowly and symptoms of GH excess are often not noticed for many years. Other adenomas grow rapidly and invade surrounding brain areas or the sinuses, which are located near the pituitary. In general, younger patients tend to have more aggressive tumors.

Most pituitary tumors arise spontaneously and are not genetically inherited. Many pituitary tumors arise from a genetic alteration in a single pituitary cell which leads to increased cell division and tumor formation. This genetic change, or mutation, is not present at birth, but is acquired during life. The mutation occurs in a gene that regulates the transmission of chemical signals within pituitary cells; it permanently switches on the signal that tells the cell to divide and secrete GH. The events within the cell that cause disordered pituitary cell growth and GH oversecretion currently are the subject of intensive research.

Other tumors

In a few patients, acromegaly is caused not by pituitary tumors but by tumors of the pancreas, lungs, and adrenal glands. These tumors also lead to an excess of GH, either because they produce GH themselves or, more frequently, because they produce GHRH, the hormone that stimulates the pituitary to make GH. In these patients, the excess GHRH can be measured in the blood and establishes that the cause of the acromegaly is not due to a pituitary defect. When these non-pituitary tumors are surgically removed, GH levels fall and the symptoms of acromegaly improve.

Read more at Wikipedia.org


[List your site here Free!]


Pituitary surgery for acromegaly - Editorial
From British Medical Journal, 9/4/99 by R N Clayton

Should be done by specialists

The objective of treatment in acromegaly is not only to alleviate symptoms, improve quality of life, and prevent complications but also to reverse the increased (two to threefold) mortality from vascular and respiratory disease and colon cancer. That this can be achieved if "target" basal growth hormone concentrations of [is less than] 5 mU/l (2.5 ng/ml) are reached has been shown,[1 2] with the proviso that serum insulin-like growth factor 1 (IGF-1) values may need to be reduced to the normal age-related reference range.[3] Transsphenoidal adenomectomy is the most rapid means of reducing serum growth hormone and IGF-1 in acromegaly. The question then arises of how effective surgery is at achieving the target growth hormone and IGF-1 values. Subsidiary issues are: (a) what determines the outcome of surgery? (b) what is the relapse rate? (c) what is the complication rate? and (d) what is the most cost effective service provision?

Surgical outcomes in terms of safe target growth hormone concentrations have recently been reported in over 1000 patients[3-11] All these series show that large tumour size, together with the degree of extrasellar extension (particularly lateral), and high preoperative serum growth hormone concentrations are major determinants of initial surgical failure. Thus, in 1999 a patient with a microadenoma ([is less than] 1 cm in diameter) or mesoadenoma ([is greater than] 1 cm but confined to the sella turcica) should have upwards of 80% chance of successful adenomectomy. However, the surgical outcome for those with a macroadenoma ([is greater than] 1 cm with extension outside the sella) is by no means so successful, with at best 60% achieving the safe target growth hormone concentration. However, even for macro-adenomas it is important to reduce the serum growth hormone level as much as possible, since the outcome of adjuvant treatment with somatostatin analogues, dopamine agonists, or radiotherapy is directly related to the pretreatment growth hormone concentration.[8]

What is new in the recent reports is the demonstration that the outcome of surgical treatment for acromegaly is related to the experience of the operator. In the study from Manchester,[8] where 73 patients were operated on by any of nine surgeons, fewer than 20% of patients achieved a growth hormone [is less than] 5 mU/l, an outcome the authors attribute to the few cases operated on by any one surgeon. Likewise, the success rate in Birmingham was also low at 33%,[5] where eight surgeons were involved. However, in Oxford, Newcastle, or St Bartholomew's Hospital, London (each of which had only one surgeon performing pituitary surgery), a patient had a chance of a successful adenomectomy of 42-56%.[4 6 10] Interestingly, Yamada et al in Japan report a doubling of the success rate when a single surgeon started operating on their patients with acromegaly (from 37% to 81%).[7] Similarly, the proportion of patients achieving the target basal growth hormone concentration of [is less than] 5 mU/l in Birmingham doubled (from 33% to 64%) when a single surgeon took over all operations.[11] The Oxford authors also report improvement in results of a single surgeon as his experience grew over 20 years.[10]

The relapse rate 5-10 years after successful initial surgery is low, at 0-7%, and major complication rates (leaks of cerebrospinal fluid, meningitis, permanent diabetes insipidus, new pituitary hypofunction) are also low, at less than 10%. Thus, in experienced centres adenomectomy for small adenomas secreting growth hormone is effective and safe and has low relapse and complication rates. However, even in the best hands some 15-20% of microadenomas and 40-50% of macroadenomas will not achieve safe growth hormone concentrations after initial surgery and will require additional long term adjunctive treatment (radiotherapy or medical treatment). Since adjunctive treatment is expensive, and may be required for many years, it is dearly in everyone's interests for people with acromegaly to be operated on by experienced pituitary surgeons. It is difficult to measure cost of treatment, but the cost of the most effective medical treatment, somatostatin analogues, alone is around 12 000 [pounds sterling] per patient per year.

Endocrinologists are normally responsible for advising patients with acromegaly. Since this is usually pituitary surgery first they should choose the "best" surgeon, even if this means referring outside their immediate local service. Not only will this be best for the patient but it will also result in the most effective use of NHS resources since fewer patients will require adjuvant treatment. Pressure must be exerted to put in place a system whereby many fewer centres and surgeons in the United Kingdom operate on patients with acromegaly and other pituitary tumours. Where this has happened, in Japan[7] and in Birmingham,[11] the effect has been dramatic.

How many centres should there be? Our own view is that the minimum population that should be served is 5 000 000, which would produce 20-30 new cases of acromegaly a year. With two surgeons per centre this would mean no more than 10 centres in the UK.

[1] Bates AS, van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Quart J Med 1993;86:293-9.

[2] Orme SM, McNally RJQ Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730-4.

[3] Swearingen B, Barker FG, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83: 3419-26.

[4] Osman IA, James RA, Chatterjee S, Mathias D, Kendall-Taylor P. Factors determining the long-term outcome of surgery for acromegaly. Quart J Med 1994;87:617-23.

[5] Jenkins S, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol 1995;43:517-22.

[6] Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996;45:407-13.

[7] Yamada S, Aiba T, Takada K, Ozawa Y, Shimizu T, Sawano S, Shishiba Y, Sano T. Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome. Clin Endocrinol 1996;45:291-8.

[8] Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JRE, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone secreting adenomas. Clin Endocrinol 1998;49:653-7.

[9] Abosch A, Tyrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Trans sphenoidal microsurgery for growth hormone secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411-18.

[10] Ahmed S, Elsheikh M, Page RCL, Adams CBT, Wass JAH. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 1999;50:561-7.

[11] Gittoes NJL, Johnson AP, Sheppard MC, Stewart PM. Outcome of surgery for acromegaly: the experience of a single surgeon. Quart J Med (in press).

R N Clayton professor of medicine

Keele University and North Staffordshire Hospital, Stoke on Trent ST4 7QB

P M Stewart professor of medicine

Queen Elizabeth Hospital, Birmingham B15 2TH

S M Shalet professor of endocrinology

Christie Hospital, Manchester M20 4BX

J A H Wass professor of endocrinology

Radcliffe Infirmary, Oxford OX2 6HE

COPYRIGHT 1999 British Medical Association
COPYRIGHT 2000 Gale Group

Return to Acromegaly
Home Contact Resources Exchange Links ebay